Concepedia

Author

Kathryn Parker

Goethe University FrankfurtORCID

Also Known As

K P Parker, K Parker, K. P. Parker, K. Parker, Kathryn Parker

26

Publications

461

Citations

10

H-Index

39

Concepts

All Affiliations

Goethe University FrankfurtThe Alfred HospitalDana-Farber Cancer InstitutePeter MacCallum Cancer CentreNovartis (United States)
KP

About

Kathryn Parker is an author at Goethe University Frankfurt specializing in medicine, pharmacotherapy, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

255

2

Social Sciences

1

1

50

3

Cognitive Science

1

1

50

4

Medical Laboratory Science

1

1

41

5

Nephrology

1

1

41

Kathryn Parker

×

10

Publications

428

Citations

10

H-Index

YearCitations

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

Daniel J. DeAngelo, Andrew Spencer, Kapil N. Bhalla,

Leukemia

2013

137

Comparison of subjective sleep quality in patients with cancer and healthy subjects.

D C Owen, Kathryn Parker, Deborah B. McGuire

PubMed

1999

70

Bdnf Deletion or TrkB Impairment in Amygdala Inhibits Both Appetitive and Aversive Learning

Scott A. Heldt, Kelsey S. Zimmermann, Kathryn Parker,

Journal of Neuroscience

2014

50

Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.

Oliver G. Ottmann, Andrew Spencer, H. Miles Prince,

Blood

2008

50

Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.

Kathryn Parker, William E. Mitch, John C. Stivelman,

Journal of the American Society of Nephrology

1997

41

Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen

José Baselga, Federico Rojo, Herlinde Dumez,

Journal of Clinical Oncology

2005

27

Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies.

Andrew Spencer, Miles Prince, Daniel J. DeAngelo,

Blood

2007

16

Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

José Baselga, Alain C. Mita, Patrick Schöffski,

Clinical Cancer Research

2012

14

Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.

Daniel J. DeAngelo, Andrew Spencer, Thomas Fischer,

Blood

2009

13

Utility of N terminal pro brain natriuretic peptide in elderly patients

David Wellsted, Kathryn Parker, Mary Lynch,

Postgraduate Medical Journal

2006

10

Page 1